Tezosentan, an endothelin receptor antagonist, limits liver injury in endotoxin challenged cirrhotic rats

Gut

Volumn 53, Issue 12, 2004, Pages 1844-1849

  Urbanowicz, W ^a   Sogni, P ^a   Moreau, R ^a   Tazi, K A ^a   Barriere, E ^a   Poirel, O ^a   Martin, A ^b   Guimont, M C ^a   Cazals Hatem, D ^a   Lebrec, D ^a  

^a BEAUJON HOSPITAL   (France)

^b AVICENNE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CYCLOOXYGENASE 2; ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR ANTAGONIST; ENDOTOXIN; INDUCIBLE NITRIC OXIDE SYNTHASE; LIPOPOLYSACCHARIDE; MYELOPEROXIDASE; PLACEBO; TEZOSENTAN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG MECHANISM; LIVER CIRRHOSIS; LIVER INJURY; LYMPHOCYTIC INFILTRATION; MALE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; STATISTICAL SIGNIFICANCE; SURVIVAL RATE;

ANIMALS; ENDOTHELINS; ENDOTOXEMIA; LIPOPOLYSACCHARIDES; LIVER; LIVER CIRRHOSIS; MALE; NEUTROPHIL INFILTRATION; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; PEROXIDASE; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ENDOTHELIN; TETRAZOLES; TRANSAMINASES; TUMOR NECROSIS FACTOR-ALPHA; VASODILATOR AGENTS;

EID: 9344219968     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2003.036517     Document Type: Article

References (39)

1. Moreau R, Hadengue A, Soupison T. Septic shock in patients with cirrhosis: hemodynamic and metabolic characteristics and intensive care unit outcomes. Crit Care Med 1992;20:746-50.
2. Caly WR, Strauss E. A prospective study of bacterial infection in patients with cirrhosis. J Hepatol 1993;18:353-8.
3. Sogni P, Moreau R, Lebrec D. Endotoxemia: an unnecessary but aggravating condition in portal hypertension? J Hepatol 1999;30:1160-2.
4. Hewett JA, Roth RA. Hepatic and extrahepatic pathobiology of bacterial lipopolisaccharides. Pharmacol Reviews 1993;4:381-404,
5. Paik YH, Schwabe RF, Bataller R, et al. Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology 2003;37:1043-55.
6. Heller J, Sogni P, Barriere E, et al. Effects of lipopolysaccharide on TNF-α production, nepatic NOS2 activity, and hepatic toxicity in rats with cirrhosis. J Hepatol 2000;33:376-81.
7. Harry D, Anand R, Holt S, et al. Increased sensitivity to endotoxemia in the bile duct-ligated cirrhotic rat. Hepatology 1999;30:1198-205.
8. Streetz K, Leifeld L, Grundmann D, et al. Tumor necrosis factor alpha in the pathogenesis of human and murine fulminant hepatic failure. Gastroenterology 2000;119:446-60.
9. Papadakis KA, Targan SR. Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology 2000;119:1148-57.
10. B receptor antagonist, in portal hypertensive rats. Hepatology 1998;28:655-9.
11. Goto M, Takei Y, Kawano S, et al. Endothelin-1 is involved in the pathogenesis of ischaemia/reperfusion liver injury by hepatic microcirculatory disturbances. Hepatology 1994;19:675-81.
12. Kawanura E, Yamanaka N, Okamoto E, et al. Response of plasma and tissue endothelin 1 to liver ischemia and its implication in ischemia-reperfusion injury. Hepatology 1995;21:1138-43.
13. Yokoyama Y, Baveja R, Sonin N, et al. Altered endothelin receptor subtype expression in hepatic injury alter ischemia/reperfusion. Shock 2000;13:72-8.
14. Gandhi CR, Sproat LA, Subbotin VM. Increased hepatic endothelin-1 levels and endothelin receptor density in cirrhotic rats. Life Sci 1996;58:55-62.
15. Pinzani M, Milani S, De Franco R, et al. Endothelin 1 is overexpressed in human cirrhotic liver and exerts multiple effects on activated hepatic stellate cells. Gastroenterology 1996;110:534-48.
16. Eakes AT, Olson MS. Regulation of endothelin synthesis in hepatic endothelial cells. Am J Physiol 1998;274:G1068-76.
17. Gerbes AL, Moller S, Gulberg V, et al. Endothelin-1 and -3 plasma concentration in patients with cirrhosis: role of splanchnic and renal passage and liver function. Hepatology 1995;21:735-9.
18. Kuddus RH, Nalesnik MA, Subbotin VM, et al. Enhanced synthesis and reduced metabolism of endothelin-1 (ET-1) by hepatocytes-an important mechanism of increased endogenous levels of ET-1 in liver cirrhosis. J Hepatol 2000;33:725-32.
19. Pittet JF, Morel DR, Hemsen A, et al. Elevated plasma endothelin-1 concentrations are associated with the severity of illness in patients with sepsis. Ann Surg 1991;213:261-4.
20. Gandhi CR, Kuddus RH, Nemoto EM, et al. Endotoxin treatment causes an uprequlation of the endothelin system in the liver: amelioration of increased portal resistance by endothelin receptor antagonism. J Gastroenterol Hepatol 2001;16:61-9.
21. McMillen MA, Sumpio BE. Endothelins: polyfunctional cytokines. J Am Coll Surgeons 1995;180:621-37.
22. Yokomori H, Oda M, Ogi M, et al. Enhanced expression of endothelin receptor subtypes in cirrhotic rat liver. Liver 2001;21:114-22.
23. Pannen BHJ, Bauer M, Zhang JX, et al. Endotoxin pretreatment enhances portal venous contractile response to endothelin-1. Am J Physiol 1996;39:H7-15.
24. Clozel M, Ramuz H, Clozel J-P, et al. Pharmacology of tezosentan, new endothelin receptor antagonist designed for parenteral use. J Pharmacol Exp Ther 1999;290:840-6.
25. Lebrec D. Animal models in portal hypertension. In: Okuda K, Benhamou JP, eds. Portal hypertension. Clinical and physiological aspects. Tokyo: Springer-Verlag, 1991:101-13.
26. Matsukawa A, Kaplan MH, Hogaboam CM, et al. Pivotal role of signal transducer and activator of transcription (Stat)4 and Stat6 in the innate immune response during sepsis. J Exp Med 2001;193:679-88.
27. Bradford MM. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
28. Cahill PA, Forster C, Redmond EM, et al. Enhanced nitric oxide synthase activity in portal hypertensive rabbits. Hepatology 1995;22:598-606.
29. Gadano AC, Sogni P, Heller J, et al. Vascular nitric oxide production during the development of two experimental models of portal hypertension. J Hepatol 1999;30:896-903.
30. Uhlmann D, Uhlmann S, Spiegel HU. Important role for endothelins in acute hepatic ischaemia/reperfusion injury. J Invest Surg 2001;14:31-45.
31. Nishida T, Huang T-P, Seiyama A, et al. Endothelin A-receptor blockade worsens endotoxin-induced hepatic microcirculatory changes and necrosis. Gastroenterology 1998;115:412-20.
32. Bradham CA, Plumpe JR, Manns MP, et al. Mechanism of hepatic toxicity. I. TNF-induced liver injury. Am J Physiol 1998;275:G387-92.
33. Wang JH, Redmond HP, Wu QD, et al. Nitric oxide mediates hepatocyte injury. Am J Physiol 1998;275:G1117-26.
34. Ou J, Carlos TM, Watkins SC, et al. Differential effects of nonselective nitric oxide synthase (NOS) and selective inducible NOS inhibition on hepatic necrosis, apoptosis, ICAM-1 expression, and neutrophil accumulation during endotoxemia. Nitric Oxide 1997;5:404-16.
35. Grobmyer SR, Armstrong RC, Nicholson SC, et al. Peptidomimetic fluoromethylketone rescues mice from lethal endotoxic shock. Mol Med 1999;5:585-94.
36. Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999;285:248-51.
37. Calanda T, Echtenacher B, Roy DL, et al. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 2000;6:164-70.
38. Bouchon A, Facchetti F, Weigand MA, et al. TREM-1 amplifies inflammation and is a crucial mediator of septic shock. Nature 2001;410:1103-7.
39. Nathan C, Ding A. TREM-1: a new regulator of innate immunity in sepsis syndrome. Nat Med 2001;7:530-2.